Drug class
Bispecific humanised monoclonal antibody; dual VEGF-A and angiopoietin-2 (Ang-2) inhibitor
Mechanism of action
Binds VEGF-A and Ang-2, inhibiting VEGF-mediated neovascularisation and vascular permeability and reducing Ang-2-mediated vascular destabilisation and inflammation in the retina.
General use cases
- Treatment of neovascular (wet) age-related macular degeneration (nAMD) in adults
- Treatment of diabetic macular oedema (DME) in adults
- Treatment of macular oedema following retinal vein occlusion (RVO) under product-specific authorisations
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
